<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00400725</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR.29060</org_study_id>
    <nct_id>NCT00400725</nct_id>
  </id_info>
  <brief_title>Maintenance Effect of Clobex Shampoo on Subjects With Moderate to Severe Scalp Psoriasis</brief_title>
  <official_title>Comparison of the Maintenance Effect of Clobex® Shampoo 0.05% Used Twice Weekly vs. Vehicle on Scalp Psoriasis in Subjects Who Successfully Responded to a 4-week Daily Course of Clobex® Shampoo 0.05%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma R&amp;D</source>
  <brief_summary>
    <textblock>
      The objective of the study is to assess the maintenance effect on scalp psoriasis of Clobex®&#xD;
      Shampoo 0.05% when used twice weekly.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Psoriasis is a chronic disease that affects the skin, the scalp and joints. Scalp psoriasis&#xD;
      is very common and can have an important impact on people's life.&#xD;
&#xD;
      Primary objective of scalp psoriasis treatments is to gain initial and rapid control of the&#xD;
      disease process with a minimum of side-effects and improve patient quality of life.&#xD;
&#xD;
      Still, one of the unmet needs of scalp psoriasis therapies is the maintenance of a long-term&#xD;
      remission. For corticosteroids in particular, one of the drawbacks is the disease recurrences&#xD;
      after cessation of the treatment.&#xD;
&#xD;
      Therefore the establishment of a modified corticosteroid dosing regimen that would allow&#xD;
      remission with minimal side-effects is suitable.&#xD;
&#xD;
      The purpose of this study is to assess how long a patient can be successfully maintained in a&#xD;
      good condition when using Clobex® shampoo only twice a week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global severity score</measure>
    <time_frame>1st relapse</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>all visits</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>end of study phases</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Scalp Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobex Shampoo 0.05%</intervention_name>
    <description>twice weekly</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clobex shampoo placebo</intervention_name>
    <description>twice weekly</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects aged 18 years or older.&#xD;
&#xD;
          -  Subjects with moderate to severe scalp psoriasis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who need systemic treatment for their body psoriasis&#xD;
&#xD;
          -  Subjects with a washout period for topical treatment(s) on the scalp less than:&#xD;
&#xD;
               -  Corticosteroids 2 weeks&#xD;
&#xD;
               -  All other anti-psoriasis medications 2 weeks&#xD;
&#xD;
          -  Subjects with a washout period for systemic treatment(s) less than:&#xD;
&#xD;
               -  PUVA therapy 4 weeks&#xD;
&#xD;
               -  Biological therapies 12 weeks&#xD;
&#xD;
               -  Treatments other than biologicals with a possible efficacy on psoriasis 4 weeks&#xD;
&#xD;
               -  Treatment known to worsen psoriasis 2 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Poulin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche Dermatologique du Quebec Métropolitain</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>centre de Recherche Dermatologique du Québec</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.clobex.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>November 16, 2006</study_first_submitted>
  <study_first_submitted_qc>November 16, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2006</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2021</last_update_posted>
  <keyword>maintenance</keyword>
  <keyword>scalp psoriasis</keyword>
  <keyword>Galderma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

